Plasmid-Mediated Carbapenem-Hydrolyzing β-Lactamase KPC-2 in Klebsiella pneumoniae Isolate from Greece

Antimicrobial Agents and Chemotherapy
2008.0

Abstract

The emergence and dissemination of Enterobacteriaceae isolates harboring carbapenemases in various geographic regions represent a significant threat to the management of nosocomial infections. Carbapenem-hydrolyzing β-lactamases can be metallo β-lactamases, expanded-spectrum oxacillinases, or Ambler class A enzymes (8, 9). The class A KPC β-lactamases hydrolyze all β-lactams except cephamycins. They are increasingly reported in data from studies of isolates of enterobacterial species (mostly Klebsiella pneumoniae species) collected in the United States, especially in New York City hospitals (1, 2, 4, 9, 12). Outside of the United States, single KPC-producing isolates containing members of the Enterobacteriaceae or containing Pseudomonas aeruginosa strains have been reported from France, China, and Colombia, but an epidemic situation has also been reported from Israel (5–7, 10, 11). We report here a K. pneumoniae isolate from Greece that produced β-lactamase KPC-2. On 17 July 2007, a 22-year-old woman was hospitalized in the intensive care unit of the hospital of Heraklion, Greece, for severe cranial trauma with coma (Glasgow coma scale score, 7) and multiple cranial and costal fractures subsequent to a traffic accident. On 10 August, she was initially transferred to the orthopedic ward and then to the intensive care unit of the hospital of Meaux, France. The day of her admission, bacteriological screening and wound samples revealed the presence of panresistant Acinetobacter baumannii (susceptible only to colistin) and of K. pneumoniae GR, which was resistant to all antibiotics except gentamicin according to disk diffusion susceptibility testing results (3). The MICs of β-lactams tested by the Etest method (AB BIODISK, Solna, Sweden) and interpreted according to CLSI standards (3) for K. pneumoniae GR showed values for expanded-spectrum cephalosporins and carbapenems only slightly modified after the addition of clavulanic acid (Table 1). A crude β-lactamase extract of that isolate showed significant carbapenem hydrolyzing activity, as measured spectrophotometrically (0.2, 0.06, and 0.05 μmol of imipenem, meropenem, and ertapenem/min/mg of total protein, respectively) (6, 8). Plasmid analysis detected a ca. 75-kb self-conjugative plasmid that conferred a β-lactam resistance pattern for Escherichia coli transconjugants that was consistent with the presence of a slightly clavulanic acid-inhibited carbapenemase (Table 1). PCR experiments using primers for detection of Ambler class A, class D, and class B β-lactamase genes (6, 8) followed by sequencing identified β-lactamase genes coding for carbapenemase KPC-2 (pI 6.8) and the narrow-spectrum TEM-1 (pI 5.4). Then, using a series of successive PCR primers, the 2.8-kb sequences surrounding the blaKPC-2 gene were found to be identical to those surrounding the same blaKPC-2 gene in a K. pneumoniae isolate from New York (6). Up to now, carbapenemases of the KPC type seemed to be limited to Israel in this Mediterranean region. This is the first evidence of the identification of carbapenemases of the KPC type in Greece, a country located near Israel. It remains to be determined to what extent the spread of KPC-type enzymes contributes to the high level of carbapenem resistance that until now had been thought to occur only in the presence of class B carbapenemases (VIM-type enzymes).

Knowledge Graph

Similar Paper

Plasmid-Mediated Carbapenem-Hydrolyzing β-Lactamase KPC-2 in Klebsiella pneumoniae Isolate from Greece
Antimicrobial Agents and Chemotherapy 2008.0
Emergence of Serratia marcescens , Klebsiella pneumoniae , and Escherichia coli Isolates Possessing the Plasmid-Mediated Carbapenem-Hydrolyzing β-Lactamase KPC-2 in Intensive Care Units of a Chinese Hospital
Antimicrobial Agents and Chemotherapy 2008.0
Plasmid-Mediated KPC-2 in a Klebsiella pneumoniae Isolate from China
Antimicrobial Agents and Chemotherapy 2007.0
Emerging Klebsiella pneumoniae Isolates Coproducing KPC-2 and VIM-1 Carbapenemases
Antimicrobial Agents and Chemotherapy 2009.0
Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland
Antimicrobial Agents and Chemotherapy 2009.0
First Identification of Pseudomonas aeruginosa Isolates Producing a KPC-Type Carbapenem-Hydrolyzing β-Lactamase
Antimicrobial Agents and Chemotherapy 2007.0
First Report of KPC-2-Producing Klebsiella pneumoniae Strains in Brazil
Antimicrobial Agents and Chemotherapy 2009.0
Plasmid-Encoded Carbapenem-Hydrolyzing β-Lactamase OXA-48 in an Imipenem-Susceptible Klebsiella pneumoniae Strain from Belgium
Antimicrobial Agents and Chemotherapy 2008.0
Molecular Epidemiology, Sequence Types, and Plasmid Analyses of KPC-Producing Klebsiella pneumoniae Strains in Israel
Antimicrobial Agents and Chemotherapy 2010.0
KPC-Producing Extreme Drug-Resistant Klebsiella pneumoniae Isolate from a Patient with Diabetes Mellitus and Chronic Renal Failure on Hemodialysis in South Korea
Antimicrobial Agents and Chemotherapy 2010.0